Description
Market Report Coverage – Carrier Screening Market
Market Segmentation
• Type (Expanded Carrier Screening and Targeted Carrier Screening)
• Product (In Vitro Diagnostics And Laboratory Developed Tests)
• Carrier Screening Type (Prenatal Carrier Screening And Preconception Carrier Screening)
• Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Microarray, And Other Technologies)
• Indication (Fragile X Syndrome, Cystic Fibrosis, Spinal Muscular Atrophy, Down’s Syndrome, Thalassemia, Tay-Sachs Disease, Huntington’s Disease, Sickle Cell Anemia, Hemophilia, and Other Indications)
Regional Segmentation
• North America: U.S., Canada
• Europe: Germany, France, U.K, Italy, Spain, Netherlands, Denmark, Belgium, Switzerland and Rest-of-Europe
• Asia-Pacific: China, Japan, India, South Korea, Australia, Singapore, Rest-of-Asia-Pacific
• Latin America: Brazil, Mexico, Rest-of-Latin America
• Rest-of-the-World
Market Growth Drivers
• Decreasing Cost of Sequencing
• Rising Emphasis on Early Detection and Prevention of Complex Genetic Disorders
• Increasing Maternal Age Leading to Pregnancy Complications
• Rising Funding and Innovation in the carrier Screening Ecosystem
Market Challenges
• Regulatory Challenges in the Field of Carrier Screening
• Lack of High Complexity Testing Centers
• Existing Diagnostic Confidence on Conventional Screening Methods
Market Opportunities
• Massive Scope for Adoption of Carrier Screening in Developing Nations
Key Companies Profiled
BGI Group, CENTOGENE N.V., Eurofins Scientific, Fulgent Genetics, Inc., Gene by Gene, Ltd., Illumina, Inc., Invitae Corporation, Laboratory Corporation of America Holdings, Myriad Genetics, Inc., Natera, Inc., OPKO Health, Quest Diagnostics Incorporated, Sema4, Thermo Fisher Scientific Inc., Yourgene Health Plc
Key Questions Answered in this Report:
• How is carrier screening revolutionizing the field of reproductive health?
• What are the major market drivers, challenges, and opportunities in the global carrier screening market?
• What are the underlying structures resulting in the emerging trends within the global carrier screening market?
• How is the COVID-19 pandemic impacting the global carrier screening ecosystem??
• What are the key development strategies that the major players are implementing in order to sustain themselves in the competitive market?
• What are the key regulatory implications in developed and developing regions pertaining to the use of carrier screening?
• What are the potential entry barriers expected to be faced by the companies willing to enter a particular region?
• How is each market segment expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each segment? Following are the segments:
o Type (expanded carrier screening and targeted carrier screening)
o Product (in vitro diagnostics and laboratory developed tests)
o Carrier Screening Type (prenatal carrier screening and preconception carrier screening)
o Technology (next-generation sequencing, polymerase chain reaction, microarray, and other technologies)
o Indication (fragile X syndrome, cystic fibrosis, spinal muscular atrophy, Down’s Syndrome, thalassemia, Tay-Sachs Disease, Huntington’s Disease, sickle cell anemia, hemophilia, and other indications)
o Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World)
• What are the growth opportunities for the carrier screening companies in the region of their operation?
• Who are the leading players with significant offerings in the global carrier screening market?
• Which companies are anticipated to be highly disruptive in the future, and why?
Market Overview
The growth of the carrier screening market is expected to be driven by the decrease in the cost of sequencing, rising emphasis on early detection and prevention of complex genetic disorders, and increasing maternal age leading to pregnancy complications.
However, there are significant challenges restraining the market growth, such as the regulatory challenges in the field of carrier screening, and the lack of high complexity testing centers. Carrier screening is a hereditary test that gives information about whether a person carries a gene for certain genetic disorders.
It is performed before or during pregnancy times. Carrier screening allows a person to find out the chances of having a child with a genetic disorder.
Carrier screening involves testing blood, saliva, or tissue extracted from inside the cheeks. In cases of genetic disorders, a person should have two affected genes to have the disorder. A person who is a carrier has only one gene for a disorder and usually does not have symptoms or have only mild symptoms.
The current market for carrier screening is majorly dominated by manufacturers and service providers such as BGI Group, CENTOGENE N.V., Eurofins Scientific, Fulgent Genetics, Inc., Gene by Gene, Ltd., Illumina, Inc., Invitae Corporation, Laboratory Corporation of America Holdings, Myriad Genetics, Inc., Natera, Inc., OPKO Health, Quest Diagnostics Incorporated, Sema4, Thermo Fisher Scientific Inc., and Yourgene Health Plc.
The global carrier screening market is projected to reach $4,479.0 million by 2031, growing from $1,187.4 million in 2020, at a CAGR of 12.67% during the forecast period 2021-2031.
The carrier screening market is an emerging market with huge growth potential. Recent technological advancements are facilitating the adoption of the technology at a rapid pace. Carrier screening are genetic tests that are used for determining if a person is a potential carrier of genetic disorders such as cystic fibrosis (CF), Down’s syndrome, Fragile X syndrome, sickle cell anemia, and spinal muscular atrophy (SMA).
Carrier screening tests are extensively used by couples considering becoming pregnant to determine the risks of passing genetic anomalies to the child. This study aims at deciphering the potential of carrier screening and its larger role in bolstering the current era of precision medicine in the field of reproductive health.
Competitive Landscape
The growth of this market can be majorly attributed to the presence of well-established guidelines regarding carrier screening, presence of established companies undertaking key business strategies, decrease in the cost of sequencing, rising emphasis on early detection and prevention of complex genetic disorders, and increasing maternal age leading to pregnancy complications, among others.
Further, increasing focus on research pertaining to carrier screening such as targeted carrier screening in spinal muscle atrophy and emerging application of preconcecption carrier screening is also expected to support the growth of the carrier screening market during the forecast period, 2021-2031.
The growth of other technologies, such as next-generation sequencing and PCR can be attributed to the increased clinical research to understand the involvement of molecular pathology in the diagnosis and prognosis of genetic disorders.
Based on region, North America holds the largest share in the market, owing to improved healthcare infrastructure, rise in per capita income, and improvised reimbursement policies in the region. However, the Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period 2021-2031.
Related Report: Live Cell Imaging Market: Market Segments: By Product (Equipment, Consumable and Software); By Technology (Time-lapse Microscopy, Fluorescence recovery after photobleaching (FRAP), Fluorescence resonance energy transfer (FRET), High content screening (HCS) and Others); By Application (Cell Biology, Developmental Biology, Stem Cell & Drug Discovery and Others); and Region – 1Analysis of Market Size, Share & Trends for 2014 – 12019 and Forecasts to 2030
Related Report: Global HERG Screening Market Research Report – Forecast till 2027
Table of Contents
1 Market
1.1 Product Definition
1.1.1 Inclusion and Exclusion
1.2 Market Scope
1.2.1 Scope of the Study
1.2.2 Key Questions Answered in the Report
1.3 Research Methodology
1.3.1 Global Carrier Screening Market: Research Methodology
1.3.2 Data Sources
1.3.2.1 Primary Data Sources
1.3.2.2 Secondary Data Sources
1.3.3 Market Estimation Model
1.3.4 Criteria for Company Profiling
1.4 Market Overview
1.4.1 Emerging Applications of Carrier Screening
1.4.2 Appropriate Use Criteria
1.4.2.1 Carrier Screening for Familial Disease
1.4.2.1.1 Fragile X Syndrome (FXS)
1.4.2.2 Carrier Screening for Common and Ethnic Genetic Diseases
1.4.2.2.1 Cystic Fibrosis
1.4.2.2.2 Spinal Muscular Atrophy
1.4.2.2.3 Hemoglobinopathy
1.4.2.2.4 Ashkenazi Jewish Carrier Screening
1.4.2.3 Other Ethnicities
1.4.3 Market Footprint and Growth Potential
1.4.4 Disruption in Global Carrier Screening Market Due to COVID-19
1.4.5 Navigating Crisis Recovery and Looking to the Future
2 Industry Analysis
2.1 Overview
2.2 Legal Requirements and Framework in the U.S.
2.2.1 U.S. Food and Drug Administration (FDA)
2.2.2 American College of Medical Genetics and Genomics (ACMG)
2.2.3 American College of Obstetricians and Gynecologists
2.3 Legal Requirements and Framework in Europe
2.4 Legal Requirements and Framework in Asia-Pacific
2.4.1 China
2.4.2 Japan
2.5 Reimbursement Analysis
3 Market Dynamics
3.1 Overview
3.2 Impact Analysis
3.3 Market Drivers
3.3.1 Decreasing Cost of Sequencing
3.3.2 Rising Emphasis on Early Detection and Prevention of Complex Genetic Disorders
3.3.3 Increasing Maternal Age Leading to Pregnancy Complications
3.3.4 Rising Funding and Innovation in the Carrier Screening Ecosystem
3.4 Market Restraints
3.4.1 Regulatory Challenges in the Field of Carrier Screening
3.4.2 Lack of High Complexity Testing Centers
3.4.3 Existing Diagnostic Confidence on Conventional Screening Methods
3.5 Market Opportunities
3.5.1 Massive Scope for Adoption of Carrier Screening in Developing Nations
4 Competitive Landscape
4.1 Overview
4.2 Product Launches
4.3 Synergistic Activities
4.4 Acquisitions
4.5 Product Approvals and Fundings
4.6 Market Share Analysis, 2019–2020
4.7 Growth Share Analysis
5 Type, $Million, 2020 – 2031
5.1 Overview
5.2 Expanded Carrier Screening
5.2.1 Customized Panel Testing
5.2.2 Predesigned Panel Testing
5.3 Targeted Carrier Screening
6 Product, $Million, 2020 – 2031
6.1 Overview
6.2 In Vitro Diagnostics (IVD)
6.3 Laboratory Developed Tests (LDT)
7 Carrier Screening Type, $Million, 2020-2031
7.1 Overview
7.2 Prenatal Carrier Screening
7.2.1 IVDs
7.2.2 LDTs
7.3 Preconception Carrier Screening
7.3.1 IVDs
7.3.2 LDTs
8 Technology, $Million, 2020 – 2031
8.1 Overview
8.2 Next-Generation Sequencing (NGS)
8.3 Polymerase Chain Reaction (PCR)
8.3.1 Real-Time Polymerase Chain Reaction (RT-PCR)
8.3.2 Digital PCR (dPCR)
8.4 Microarray
8.5 Other Technologies
9 Indication, $Million, 2020 – 2031
9.1 Overview
9.2 Fragile X syndrome
9.3 Cystic Fibrosis
9.4 Spinal Muscular Atrophy
9.5 Down’s Syndrome
9.6 Thalassemia
9.7 Tay-Sachs Disease
9.8 Huntington’s Disease
9.9 Sickle Cell Anemia
9.1 Hemophilia
9.11 Other Indication
10 Region, $Million, 2020-2031
10.1 Overview
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 France
10.3.3 U.K.
10.3.4 Italy
10.3.5 Spain
10.3.6 Netherlands
10.3.7 Denmark
10.3.8 Belgium
10.3.9 Switzerland
10.3.10 Rest-of-Europe
10.4 Asia-Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 South Korea
10.4.5 Australia
10.4.6 Singapore
10.4.7 Rest-of-Asia-Pacific (RoAPAC)
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Rest-of-Latin America (RoLA)
10.6 Rest-of-the-World
10.6.1 Middle East
10.6.2 Rest-of-Rest-of-the-World
11 Company Profiles
11.1 Overview
11.2 BGI Group
11.2.1 Company Overview
11.2.2 Role of BGI Group in the Global Carrier Screening Market
11.2.3 SWOT Analysis
11.3 CENTOGENE N.V.
11.3.1 Company Overview
11.3.2 Role of CENTOGENE N.V. in the Global Carrier Screening Market
11.3.3 Financials
11.3.4 Key Insights About Financial Health of the Company
11.3.5 SWOT Analysis
11.4 Eurofins Scientific
11.4.1 Company Overview
11.4.2 Role of Eurofins Scientific in the Global Carrier Screening Market
11.4.3 Financials
11.4.4 SWOT Analysis
11.5 Fulgent Genetics, Inc.
11.5.1 Company Overview
11.5.2 Role of Fulgent Genetics, Inc. in the Global Carrier Screening Market
11.5.3 Financials
11.5.4 Key Insights About Financial Health of the Company
11.5.5 SWOT Analysis
11.6 Gene by Gene, Ltd.
11.6.1 Company Overview
11.6.2 Role of Gene by Gene, Ltd. in the Global Carrier Screening Market
11.6.3 SWOT Analysis
11.7 Illumina, Inc.
11.7.1 Company Overview
11.7.2 Role of Illumina, Inc. in the Global Carrier Screening Market
11.7.3 Financials
11.7.4 Key Insights About Financial Health of the Company
11.7.5 SWOT Analysis
11.8 Invitae Corporation
11.8.1 Company Overview
11.8.2 Role of Invitae Corporation in the Global Carrier Screening Market
11.8.3 Financials
11.8.4 Key Insights About Financial Health of the Company
11.8.5 SWOT Analysis
11.9 Laboratory Corporation of America Holdings
11.9.1 Company Overview
11.9.2 Role of Laboratory Corporation of America Holdings in the Global Carrier Screening Market
11.9.3 Financials
11.9.2 SWOT Analysis
11.1 Myriad Genetics, Inc.
11.10.1 Company Overview
11.10.2 Role of Myriad Genetics, Inc. in the Global Carrier Screening Market
11.10.3 Financials
11.10.4 Key Insights About Financial Health of the Company
11.10.5 SWOT Analysis
11.11 Natera, Inc.
11.11.1 Company Overview
11.11.2 Role of Natera, Inc. in the Global Carrier Screening Market
11.11.3 Financials
11.11.4 Key Insights About Financial Health of the Company
11.11.5 SWOT Analysis
11.12 OPKO Health
11.12.1 Company Overview
11.12.2 Role of OPKO Health in the Global Carrier Screening Market
11.12.3 Financials
11.12.4 Key Insights About Financial Health of the Company
11.12.5 SWOT Analysis
11.13 Quest Diagnostics Incorporated
11.13.1 Company Overview
11.13.2 Role of Quest Diagnostics Incorporated in the Global Carrier Screening Market
11.13.3 Financials
11.13.4 SWOT Analysis
11.14 Sema4
11.14.1 Company Overview
11.14.2 Role of Sema4 in the Global Carrier Screening Market
11.14.3 SWOT Analysis
11.15 Thermo Fisher Scientific Inc.
11.15.1 Company Overview
11.15.2 Role of Thermo Fisher Scientific Inc. in the Global Carrier Screening Market
11.15.3 Financials
11.15.4 Key Insights About Financial Health of the Company
11.15.5 SWOT Analysis
11.16 Yourgene Health Plc
11.16.1 Company Overview
11.16.2 Role of Yourgene Health Plc in the Global Carrier Screening Market
11.16.3 Financials
11.16.4 Key Insights About Financial Health of the Company
11.16.5 SWOT Analysis
List of Figures
Figure 1: Decreasing Cost and Increasing Output (TB) of Genome Sequencing (2009-2025)
Figure 2: Impact Analysis of Market Drivers and Market Challenges on the Global Carrier Screening Market
Figure 3: Global Carrier Screening Market (by Type), $Million, 2020 and 2031
Figure 4: Global Carrier Screening Market (by Product), $Million, 2020 and 2031
Figure 5: Global Carrier Screening Market (by Technology), $Million, 2020 and 2031
Figure 6: Global Carrier Screening Market (by Indication), $Million, 2020 and 2031
Figure 7: Global Carrier Screening Market (by Carrier Screening Type), $Million, 2020 and 2031
Figure 8: Global Carrier Screening Market Snapshot
Figure 9: Global Carrier Screening Market: Segmentation
Figure 10: Global Carrier Screening Market: Methodology
Figure 11: Primary Research Methodology
Figure 12: Bottom-Up Approach (Segment-Wise Analysis)
Figure 13: Top-Down Approach (Segment-Wise Analysis)
Figure 14: Global Carrier Screening Market, $Million, 2020-2031
Figure 15: Global Carrier Screening Market: COVID-19 Impact Analysis
Figure 16: Europe In Vitro Diagnostic Devices Regulation Regulatory Process
Figure 17: China NMPA Regulatory Approval Process
Figure 18: Decreasing Cost and Increasing Output (TB) of Genome Sequencing (2009-2025)
Figure 19: Share of Key Developments and Strategies, January 2018-December 2021
Figure 20: Number of Product Launches (by Company), January 2018–December 2021
Figure 21: Share of Synergistic Activities (by Company), January 2018-December 2021
Figure 22: Share of Acquisitions (by Company), January 2018-November 2021
Figure 23: Share of Product Approvals and Fundings (by Company), January 2018-November 2021
Figure 24: Market Share Analysis for Global Carrier Screening Market, $Million, 2019 and 2020
Figure 25: Growth Share Analysis for Global Carrier Screening Market (by Company), 2020
Figure 26: Global Carrier Screening Market (by Type)
Figure 27: Global Carrier Screening Market (by Type), $Million, 2020 and 2031
Figure 28: Global Carrier Screening Market (Expanded Carrier Screening), $Million, 2020-2031
Figure 29: Global Carrier Screening Market (Customized Panel Testing), $Million, 2020-2031
Figure 30: Global Carrier Screening Market (Predesigned Panel Testing), $Million, 2020-2031
Figure 31: Global Carrier Screening Market (Targeted Carrier Screening), $Million, 2020-2031
Figure 32: Global Carrier Screening Market (by Product)
Figure 33: Global Carrier Screening Market (by Product), $Million, 2020 and 2031
Figure 34: Global Carrier Screening Market (IVD), $Million, 2020-2031
Figure 35: Global Carrier Screening Market (Laboratory Developed Tests (LDT)), $Million, 2020-2031
Figure 36: Global Carrier Screening Market (by Carrier Screening type)
Figure 37: Global Carrier Screening Market (by Type), $Million, 2020 and 2031
Figure 38: Global Carrier Screening Market (Prenatal Carrier Screening), $Million, 2020-2031
Figure 39: Global Carrier Screening Market (Prenatal Carrier Screening (IVDs)), $Million, 2020-2031
Figure 40: Global Carrier Screening Market (Prenatal Carrier Screening,(LDTs)), $Million, 2020-2031
Figure 41: Global Carrier Screening Market (Preconception Carrier Screening), $Million, 2020-2031
Figure 42: Global Carrier Screening Market (Preconception Carrier Screening (IVDs)), $Million, 2020-2031
Figure 43: Global Carrier Screening Market (Preconception Carrier Screening (LDTs)), $Million, 2020-2031
Figure 44: Global Carrier Screening Market (by Technology)
Figure 45: Global Carrier Screening Market (by Technology), $Million, 2020 and 2031
Figure 46: Global Carrier Screening Market (Next-Generation Sequencing), $Million, 2020-2031
Figure 47: Global Carrier Screening Market (Polymerase Chain Reaction), $Million, 2020-2031
Figure 48: Global Carrier Screening Market (Polymerase Chain Reaction), $Million, 2020 and 2031
Figure 49: Global Carrier Screening Market (RT-PCR), $Million, 2020-2031
Figure 50: Global Carrier Screening Market (dPCR), $Million, 2020-2031
Figure 51: Global Carrier Screening Market (Microarray), $Million, 2020-2031
Figure 52: Global Carrier Screening Market (Other Technologies), $Million, 2020-2031
Figure 53: Global Carrier Screening Market (by Indication)
Figure 54: Global Carrier Screening Market (by Indication), $Million, 2020 and 2031
Figure 55: Global Carrier Screening Market (Fragile X Syndrome), $Million, 2020-2031
Figure 56: Global Carrier Screening Market (Cystic Fibrosis), $Million, 2020-2031
Figure 57: Global Carrier Screening Market (Spinal Muscular Atrophy), $Million, 2020-2031
Figure 58: Global Carrier Screening Market (Down’s Syndrome), $Million, 2020-2031
Figure 59: Global Carrier Screening Market (Thalassemia), $Million, 2020-2031
Figure 60: Global Carrier Screening Market (Tay-Sachs Disease), $Million, 2020-2031
Figure 61: Global Carrier Screening Market (Huntington’s Disease), $Million, 2020-2031
Figure 62: Global Carrier Screening Market (Sickle Cell Anemia), $Million, 2020-2031
Figure 63: Global Carrier Screening Market (Hemophilia), $Million, 2020-2031
Figure 64: Global Carrier Screening Market (Other Indication), $Million, 2020-2031
Figure 65: Global Carrier Screening (by Region): Market Snapshot
Figure 66: Global Carrier Screening Market (by Region), $Million, 2020-2031
Figure 67: Global Carrier Screening Market (by Region), $Million, 2020 and 2031
Figure 68: North America Carrier Screening Market, $Million, 2020-2031
Figure 69: North America Carrier Screening Market (by Country), $Million, 2020-2031
Figure 70: U.S. Carrier Screening Market, $Million, 2020-2031
Figure 71: Canada Carrier Screening Market, $Million, 2020-2031
Figure 72: Europe Carrier Screening Market, $Million, 2020-2031
Figure 73: Europe Carrier Screening Market (by Country), $Million, 2020–2031
Figure 74: Germany Carrier Screening Market, $Million, 2020-2031
Figure 75: France Carrier Screening Market, $Million, 2020-2031
Figure 76: U.K. Carrier Screening Market, $Million, 2020-2031
Figure 77: Italy Carrier Screening Market, $Million, 2020-2031
Figure 78: Spain Carrier Screening Market, $Million, 2020-2031
Figure 79: Netherlands Carrier Screening Market, $Million, 2020-2031
Figure 80: Denmark Carrier Screening Market, $Million, 2020-2031
Figure 81: Belgium Carrier Screening Market, $Million, 2020-2031
Figure 82: Switzerland Carrier Screening Market, $Million, 2020-2031
Figure 83: Rest-of-Europe Carrier Screening Market, $Million, 2020-2031
Figure 84: Asia-Pacific Carrier Screening Market, $Million, 2020-2031
Figure 85: APAC Carrier Screening Market (by Country), $Million, 2020-2031
Figure 86: China Carrier Screening Market, $Million, 2020-2031
Figure 87: Japan Carrier Screening Market, $Million, 2020-2031
Figure 88: India Carrier Screening Market, $Million, 2020-2031
Figure 89: South Korea Carrier Screening Market, $Million, 2020-2031
Figure 90: Australia Carrier Screening Market, $Million, 2020-2031
Figure 91: Singapore Carrier Screening Market, $Million, 2020-2031
Figure 92: RoAPAC Carrier Screening Market, $Million, 2020-2031
Figure 93: Latin America Carrier Screening Market, $Million, 2020-2031
Figure 94: Latin America Carrier Screening Market (by Country), $Million, 2020-2031
Figure 95: Brazil Carrier Screening Market, $Million, 2020-2031
Figure 96: Mexico Carrier Screening Market, $Million, 2020-2031
Figure 97: RoLA Carrier Screening Market, $Million, 2020-2031
Figure 98: RoW Carrier Screening Market, $Million, 2020-2031
Figure 99: Middle East Carrier Screening Market, $Million, 2020-2031
Figure 100: Rest-of-Rest-of-the-World Carrier Screening Market, $Million, 2020-2031
Figure 101: Total Number of Companies Profiled
Figure 102: BGI Group: Product Portfolio
Figure 103: BGI Group: SWOT Analysis
Figure 104: CENTOGENE N.V.: Portfolio
Figure 105: CENTOGENE N.V.: Overall Financials, 2018-2020
Figure 106: CENTOGENE N.V.: Revenue (by Business Segment), 2018–2020
Figure 107: CENTOGENE N.V.: Revenue (by Region), 2018-2020
Figure 108: CENTOGENE N.V.: R&D Expenditure, 2018-2020
Figure 109: CENTOGENE N.V.: SWOT Analysis
Figure 110: Eurofins Scientific: Portfolio
Figure 111: Eurofins Scientific: Overall Financials, 2018-2020
Figure 112: Eurofins Scientific: Revenue (by Region), 2018-2020
Figure 113: Eurofins Scientific: SWOT Analysis
Figure 114: Fulgent Genetics, Inc.: Portfolio
Figure 115: Fulgent Genetics, Inc.: Overall Financials, 2018-2020
Figure 116: Fulgent Genetics, Inc.: Revenue (by Region), 2018-2020
Figure 117: Fulgent Genetics, Inc.: R&D Expenditure, 2018-2020
Figure 118: Fulgent Genetics, Inc.: SWOT Analysis
Figure 119: Gene by Gene, Ltd.: Portfolio
Figure 120: Gene by Gene, Ltd.: SWOT Analysis
Figure 121: Illumina, Inc.: Product Portfolio
Figure 122: Illumina, Inc.: Overall Financials, 2018-2020
Figure 123: Illumina, Inc.: Revenue (by Business Segment), 2018–2020
Figure 124: Illumina, Inc.: Revenue (by Region), 2018–2020
Figure 125: Illumina, Inc.: R&D Expenditure, 2018-2020
Figure 126: Illumina, Inc.: SWOT Analysis
Figure 127: Invitae Corporation: Portfolio
Figure 128: Invitae Corporation: Overall Financials, 2018-2020
Figure 129: Invitae Corporation: Revenue (by Business Segment), 2018–2020
Figure 130: Invitae Corporation: Revenue (by Region), 2018-2020
Figure 131: Invitae Corporation: R&D Expenditure, 2018-2020
Figure 132: Invitae Corporation: SWOT Analysis
Figure 133: Laboratory Corporation of America Holdings: Portfolio
Figure 134: Laboratory Corporation of America Holdings: Overall Financials, 2018-2020
Figure 135: Laboratory Corporation of America Holdings: Revenue (by Segment), 2018-2020
Figure 136: Laboratory Corporation of America Holdings: Revenue (by Region), 2018-2020
Figure 137: Laboratory Corporation of America Holdings: SWOT Analysis
Figure 138: Myriad Genetics, Inc.: Portfolio
Figure 139: Myriad Genetics, Inc.: Overall Financials, 2018-2020
Figure 140: Myriad Genetics, Inc.: Revenue (by Business Segment), 2018–2020
Figure 141: Myriad Genetics, Inc.: Revenue (by Region), 2018-2020
Figure 142: Myriad Genetics, Inc.: R&D Expenditure, 2018-2020
Figure 143: Myriad Genetics, Inc.: SWOT Analysis
Figure 144: Natera, Inc.: Portfolio
Figure 145: Natera, Inc.: Overall Financials, 2018-2020
Figure 146: Natera, Inc.: Revenue (by Business Segment), 2018–2020
Figure 147: Natera, Inc.: Revenue (by Region), 2018-2020
Figure 148: Natera, Inc.: R&D Expenditure, 2018-2020
Figure 149: Natera, Inc.: SWOT Analysis
Figure 150: OPKO Health: Portfolio
Figure 151: OPKO Health: Overall Financials, 2018-2020
Figure 152: OPKO Health: Revenue (by Business Segment), 2018–2020
Figure 153: OPKO Health: Revenue (by Region), 2018-2020
Figure 154: OPKO Health: R&D Expenditure, 2018-2020
Figure 155: OPKO Health: SWOT Analysis
Figure 156: Quest Diagnostics Incorporated: Portfolio
Figure 157: Quest Diagnostics Incorporated: Overall Financials, 2018-2020
Figure 158: Quest Diagnostics Incorporated: Revenue (by Segment), 2018-2020
Figure 159: Quest Diagnostics Incorporated: SWOT Analysis
Figure 160: Sema4: Portfolio
Figure 161: Sema4: SWOT Analysis
Figure 162: Thermo Fisher Scientific Inc.: Product Portfolio
Figure 163: Thermo Fisher Scientific Inc.: Overall Financials, 2018-2020
Figure 164: Thermo Fisher Scientific Inc.: Revenue (by Business Segment), 2018–2020
Figure 165: Thermo Fisher Scientific Inc.: Revenue (by Region), 2018–2020
Figure 166: Thermo Fisher Scientific Inc.: R&D Expenditure, 2018-2020
Figure 167: Thermo Fisher Scientific Inc.: SWOT Analysis
Figure 168: Yourgene Health Plc: Portfolio
Figure 169: Yourgene Health plc: Overall Financials, 2018-2020
Figure 170: Yourgene Health Plc: Revenue (by Business Segment), 2019–2020
Figure 171: Yourgene Health Plc: Revenue (by Region), 2018–2020
Figure 172: Yourgene Health Plc: R&D Expenditure, 2018-2020
Figure 173: Yourgene Health Plc: SWOT Analysis
List of Tables
Table 1: Classification of Medical Device
Table 2: Likert Scale
Table 3: Impact Analysis of Market Drivers
Table 4: Impact Analysis of Market Restraints
Table 5: Companies Providing Expanded Carrier Screening
Table 6: Companies Providing Customized Panel Testing
Table 7: Companies Offering Predesigned Panel Testing
Table 8: Companies Offering Fragile X Syndrome Tests
Table 9: Companies Offering Cystic Fibrosis Tests
Table 10: Companies Offering Thalassemia Tests
Table 11: Companies Offering Huntington’s Disease Tests
Table 12: Companies Offering Sickle Cell Anemia Test
Table 13: Companies Offering Hemophilia Test
Table 14: North America: Market Dynamics
Table 15: Europe: Market Dynamics
Table 16: APAC: Market Dynamics
Table 17: Latin America: Market Dynamics
